Tempus AI: Winning With Precision Medicine

Stone Fox Capital Investing Group Leader Follow Summary Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Recent cancer vaccine developments from Merck and Moderna reinforce the strategic relevance and growth runway for TEM's platform. The company already had strong momentum with higher test ASPs, with the cancer tests a huge bonus. The stock was relatively cheap at 6x 2027 sales targets, and the recent developments could increase growth rates and expand the multiples the market is willing to pay for Tempus. This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Learn More » Andrei Sauko/iStock via Getty Images Tempus AI, Inc. ( TEM ) continues to remain bullish on precision medicine, especially after the cancer vaccine news from Moderna ( MRNA ). The acquisition of Personalis ( PSNL ) fits This article was written by Stone Fox Capital 56.55K Followers Follow Stone Fox Capital is an RIA from Oklahoma. Mark Holder is a CPA with degrees in Accounting and Finance. He is also Series 65 licensed and has 30 years of investing experience, including 15 years as a portfolio manager. Mark leads the investing group Out Fox The Street where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direct chat with Mark for questions. Learn more. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in TEM over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.